Skip to main content
OpenTrials
Completed

NCT Number: NCT03404635

Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism

Prospective, multicenter observational study, of the effectiveness of a standard of care protocol implemented to enhance home treatment of VTE. Study population will be selected as part of usual care as eligible for home treatment. Study personnel will travel to participating institutions to qualify the sites, deliver a Powerpoint® lecture to introduce the protocol, meet and train site principal investigators, emergency physicians and research personnel on the implementation of the protocol as part of usual clinical care, and data collection methods for a quality assurance registry with plans to use the data collected in this registry in future publications. Follow-up will be 30 days using medical records and/or telephone interview to assess for primary outcomes of bleeding or VTE recurrence.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Eskenazi Health System, Indianapolis, Indiana, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must be low risk, as defined by either A or B below:

A. The modified Hestia criteria:

  • Systolic blood pressure > 100 mm Hg
  • No thrombolysis needed
  • No active bleeding
  • SaO2 >94% while breathing room air
  • Not already anticoagulated
  • No more than two doses of IV narcotics in the emergency department
  • Other medical or social reasons to admit
  • Creatinine clearance >30mL/min
  • Not pregnant, severe liver disease or heparin induced thrombocytopenia OR

B. The physician opinion that a patients' overall social and medical situation is favorable for home treatment and the patient has a zero score on the simplified pulmonary embolism severity index (sPESI).

All of the following must true:

  • Age < 81 years
  • No history of cancer
  • No history of heart failure or chronic lung disease
  • Pulse < 110 beats/min
  • SBP > 99 mm Hg
  • O2 sat >89%%

We have chosen either criteria because both have been found equal in terms of safety for outpatient treatment of PE.6,22 Hestia includes implicit questions that most emergency physicians would use as criteria for discharge (e.g., overall medical status and social situation), whereas sPESI does not. For that reason, we have added the additional gestalt assessment question about physician discretion.

  • Patients must be discharged in <24 hours after triage in an ED visit with diagnosis of VTE using objective criteria in the emergency department.

Exclusion criteria

  • VTE diagnosis while taking anticoagulants with evidence of compliance (e.g., physician opinion that patient is taking a Eliquis®, Xarelto® or Pradaxa®, low molecular weight heparin injections or warfarin as prescribed for any condition)
  • Sensitivity or contraindication to use of apixaban
  • Troponin assay value, drawn as part of usual care and found to be positive, using local standards
  • High risk for hemorrhage defined by a score>1.5 using the method of Ruiz Gimenez.3 (Note that several criteria are already excluded by Hestia):

Recent major bleeding, 2 points Creatinine levels >1.2 mg/dl, 1.5 points Anemia, 1.5 points Cancer, 1 point Clinically overt PE, 1 point Age >75 years, 1 point

Treatment and study plan

Apixaban

Drug

Apixaban as standard of care for VTE

Rivaroxaban

Drug

Rivaroxaban as standard of care for VTE

Primary outcomes

  1. Number of re-hospitalization visits for VTE recurrence or bleeding

    Time frame: 30 days

    Re-hospitalization for > 24 hours due to VTE recurrence or bleeding

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Collaborators

  • Bristol-Myers Squibb
  • Janssen Pharmaceuticals
  • Pfizer

Registry information

Official study title

Monotherapy Anticoagulation To Expedite Home Treatment of Venous

Acronym: MATHVTE

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Jan 19, 2018
Registry last updated
Aug 7, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.